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Abstract
Background: To decrease the burden of disease of rheumatoid arthritis (RA), patients at risk for RA need to be
identified as early as possible, preferably when no clinically apparent synovitis can be detected. Up to now, it has
been fairly difficult to identify those patients with arthralgia who develop inflammatory arthritis (IA), but recent
studies using ultrasound (US) suggest that earlier detection is possible. We aimed to identify patients with arthralgia
developing IA within 1 year using US to detect subclinical synovitis at first consultation.
Methods: In a multi-centre cohort study, we followed patients with arthralgia with at least two painful joints of the
hands, feet or shoulders without clinical synovitis over 1 year. Symptom duration was < 1 year, and symptoms were
not explained by other conditions. At baseline and at 6 and 12 months, data were collected for physical
examinations, laboratory values and diagnoses. At baseline, we examined 26 joints ultrasonographically (bilateral
metacarpophalangeal joints 2–5, proximal interphalangeal joints 2–5, wrist and metatarsophalangeal joints 2–5).
Scoring was done semi-quantitatively on greyscale (GS; 0–3) and power Doppler (PD; 0–3) images. US synovitis was
defined as GS ≥ 2 and/or PD ≥ 1. IA was defined as clinical soft tissue swelling. Sensitivity and specificity were used
to assess the diagnostic value of US for the development of IA. Univariate logistic regression was used to analyse
the association between independent variables and the incidence of IA. For multivariate logistic regression, the
strongest variables (p < 0.157) were selected. Missing values for independent variables were imputed.
Results: A total of 196 patients were included, and 159 completed 12 months of follow-up. Thirty-one (16%)
patients developed IA, of whom 59% showed US synovitis at baseline. The sensitivity and specificity of US synovitis
were 59% and 68%, respectively. If no joints were positive on US, negative predictive value was 89%. In the
multivariate logistic regression, age (OR 1.1), the presence of morning stiffness for > 30 minutes (OR 3.3) and PD
signal (OR 3.4) were associated with incident IA.
Conclusions: The presence of PD signal, morning stiffness for > 30 minutes and age at baseline were independently
associated with the development of IA. Regarding the value of US in the diagnostic workup of patients with early
arthralgia at risk for IA, US did perform well in ruling out IA in patients who did not have US synovitis.
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Background
Rheumatoid arthritis (RA) is a debilitating chronic auto-
immune disease. Early initiation of effective disease-
modifying drugs can slow disease progression and dimin-
ish joint damage [1, 2]. It could be that starting disease-
modifying anti-rheumatic drug (DMARD) therapy in the
arthralgia phase or even before that could lead to better
patient outcomes [3, 4]. Until now, it has been fairly diffi-
cult to identify those patients with arthralgia who would
benefit from such early initiation of DMARD therapy be-
cause only those who would have subsequently developed
inflammatory arthritis (IA) related to a chronic inflamma-
tory joint disease would benefit from such an early inter-
vention. Recent technical developments in magnetic
resonance imaging (MRI) and ultrasound (US) suggest
that earlier detection of inflammation should be possible
before clinical manifestation [5].
We know from previous research that 15% of patients
with arthralgia who presented without clinical signs of in-
flammation at baseline would be diagnosed with IA 1 year
later, half of whom were anti-citrullinated protein antibody
(ACPA)-positive [6]. Although ACPA positivity is a very
good predictor for those patients who will develop IA
within 1 year, it is still difficult to identify the exact individ-
uals who will develop IA, because any ACPA-positive indi-
vidual has an a priori chance of 50% of developing IA. In
seronegative patients, the prediction of IA is even more dif-
ficult, because only 5% develop IA within the subsequent
year. Imaging techniques have been shown to be able to de-
tect synovitis before its clinical appearance and could be of
help in identifying those at risk of IA [5, 7]. MRI and US
are both available in the daily rheumatology clinic. MRI has
the disadvantage of being time-consuming, thereby con-
straining the number of joints which that can be assessed.
In addition, MRI is expensive and not accessible for every-
one (e.g., joint replacement, pacemaker). US is more
operator-dependent because, owing to probe position, mul-
tiple examiners can make different observations. However,
US is more flexible and easily applied in the clinic. In this
study, we aimed to identify which patients with arthralgia
will develop clinically apparent IA within 1 year using US
to detect subclinical synovitis at first consultation added to
demographic and clinical variables.
Methods
This study was a multi-centre (three centres) prospective
cohort study in which we followed patients with inflam-
matory joint complaints for 1 year.
Patients
Patients with inflammatory joint complaints of the
hands, feet or shoulders without clinically apparent
synovitis in any joint were recruited from the outpatient
clinic. Patients had a symptom duration < 1 year which
could not be explained by other conditions, such as IA,
fibromyalgia, overuse or trauma. To distinguish inflam-
matory arthralgia from other forms of arthralgia, pa-
tients had to have at least two painful joints in hands,
feet or shoulders and two of the following criteria
adapted from the Rotterdam Early Arthritis Cohort
(REACH) trial [8]: morning stiffness for more than 1 h,
unable to clench a fist in the morning, pain when shak-
ing someone’s hand, pins and needles in the fingers, dif-
ficulties wearing rings or shoes, family history of RA
and/or unexplained fatigue for < 1 year. Patients had to
be able to understand, speak and write in Dutch. Pa-
tients received treatment as the rheumatologists saw fit,
but no DMARDs were prescribed at first consultation.
Written informed consent was obtained from the partic-
ipants according to the Declaration of Helsinki. The
study was approved by the medical ethics committee of
Erasmus MC, University Medical Centre Rotterdam,
Rotterdam, The Netherlands (MEC-2010-353) and was
assessed for feasibility by the local ethical bodies of
Maasstad Hospital and Vlietland Hospital.
Clinical examination
A trained research nurse collected data about articular
symptoms, extra-articular symptoms, family history and
previous medical history. Data collection at baseline and
at 6-month and 12-month follow-up included a detailed
medical examination (swollen joint count in 44 joints,
tender joint count in 44 joints), laboratory variables
(ACPA, rheumatoid factor [RF], erythrocyte sedimenta-
tion rate), diagnosis and medications used. Observed soft
tissue swelling needed to be confirmed as an arthritis by
the treating rheumatologist. Because substantial loss to
follow-up was expected at the start of the study due to
the nature of recovering arthralgia for the majority of
patients, a telephone interview was scheduled if patients
did not want to return to the clinic for their 6- and 12-
month evaluations. Patients were asked about their clin-
ical symptoms. If the interviewer doubted the potential
presence of clinical synovitis, patients were asked to re-
turn to the outpatient clinic for clinical evaluation.
US examination
At baseline, trained US examiners blinded to the partici-
pants’ clinical details performed US following the
European League Against Rheumatism (EULAR) guide-
lines concerning patient position and scanning planes
[9]. To minimise inter-variability, US examiners followed
a standardised scanning protocol regarding acquisition
and scoring. The US machine used was the MyLab60
(Esaote, Genoa, Italy) with a high-frequency linear array
probe (LA435, 10–18 MHz). Twenty-six joints were
evaluated using greyscale (GS) and power Doppler (PD)
imaging. We scanned metatarsophalangeal joints (MTP)
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2–5 (dorsal aspect), metacarpophalangeal joints (MCP)
2–5, proximal interphalangeal joints (PIP) 2–5 (dorsal
and palmar aspects) and the wrist (radiocarpal and inter-
carpal joints). A single midline (longitudinal 12 o’clock
position) scan perpendicular to the bone surface was
used as advised by the Outcome Measures in Rheuma-
tology (OMERACT) US working group [10]. The follow-
ing PD settings were used. Colour gain was set at the
disappearance of colour noise. The pulse repetition fre-
quency was set as low as possible to have maximum sen-
sitivity but minimising noise, which resulted in a
frequency of 750 Hz. We adjusted the size and position
of the colour box to include the subcutaneous tissue to
recognize artefacts caused by vessels above the joint
[11]. PD signals were measured only in joints with a GS
score ≥ 1. The total scanning time was ½ h per patient
per session. The treating rheumatologist and the re-
search nurse were blinded to the results of the US exam-
inations at baseline.
US evaluation
Image evaluation followed the recommendations of the
Spanish Society of Rheumatology, which is a modified
version of the previously developed OMERACT defini-
tions of sonographic pathology [12]. Joints were graded
according to a semi-quantitative scoring system (0–3)
for both GS and PD images. For GS, all joints were
graded as follows: 0 = no capsular distention; 1 = hypoe-
choic material only at the level of the joint margins; 2 =
partial distention of the whole capsule, which appears
mostly concave or flat; and 3 = complete distention of
the whole capsule, which appears mostly convex. Syn-
ovial vascularisation was measured using PD and graded
as follows: 0 = absent, 1 = mild single-vessel signal or iso-
lated signal, 2 =moderate confluent vessels, and 3 =
marked vessel signals in more than half of the intra-
articular area [13]. US synovitis was defined as GS grade
2 or 3 and/or presence of PD (grade 1, 2 or 3).
Outcome
One-year incident IA was defined as clinical soft tissue
swelling. Observed soft tissue swelling needed to be con-
firmed as an arthritis by the treating rheumatologist,
who was unaware of the US findings.
Statistical analysis
If patients had no clinical evaluation for both their 6- and
12-month visits, they were classified as lost to follow-up
and not included in the analysis. Simple descriptions were
used to report baseline characteristics and the US findings.
Depending on the distribution of the data, we used the in-
dependent t test or Wilcoxon-Mann-Whitney test to exam-
ine differences between cases and non-cases. Frequencies
were compared using a chi-square test. Sensitivity and
specificity were used to assess the diagnostic value of US
for the development of IA.
After consideration of the available literature [14, 15],
we identified the following variables as relevant in the
association with emerging IA: demographic characteris-
tics (age, sex), clinical characteristics (tender joint count,
high positive autoantibodies [ACPA, RF], morning stiff-
ness lasting ≥ 30 minutes) and US findings (presence of
US synovitis, positive PD signal in at least one joint)
[14–16]. These variables were tested for their association
with IA using univariate logistic regression. For multi-
variate logistic regression, we used a backward stepwise
model procedure to select the strongest predictors (p =
0.157) [17]. A p value of 0.157 is equal to the Akaike in-
formation criterion for predictors with one regression
coefficient and is recommended for use in stepwise se-
lection of predictors [18]. Missing values of independent
variables were handled by multiple imputation using the
STATA multiple imputation by chained equations rou-
tine (M = 20) [19]. Analysis was done using STATA 14
software (StataCorp, College Station, TX, USA).
Results
In total, 297 patients were recruited to participate. The
flowchart in Fig. 1 shows the distribution of patients dur-
ing follow-up. At baseline, 196 patients met the inclusion
criteria. One hundred seventy-eight patients (91%)
returned for their clinical evaluation at 6 months, and 159
patients (81%) had their 12-month assessment. We could
determine our primary outcome for 174 patients (89%).
In total, 31 (16%) patients had developed IA within 1 year
of follow-up, of whom 15 had started DMARD therapy.
Twenty-two patients had no definite diagnosis: 12 patients
had mono-arthritis, and 10 patients had poly-arthritis. A
definite diagnosis after 12 months was given for nine pa-
tients (RA: n = 4; psoriatic arthritis: n = 4; spondyloarthritis:
n = 1). Baseline characteristics of patients with IA and non-
IA patients are shown in Table 1. We found a statistically
significant difference in baseline characteristics between the
Fig. 1 Flowchart showing the distribution of patients
during follow-up
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IA and non-IA groups for age (mean 50 vs 44 years; p =
0.005). In addition, US synovitis was found more often in
patients with IA than in non-IA subjects (59% vs 32%; p =
0.007), and PD signal was present in 31% of the patients
with IA vs 12% of the non-IA patients (p = 0.012).
US findings
US findings are described in more detail in Table 2. In total,
72 patients with arthralgia (37%) had US synovitis, of whom
29 had a positive PD signal. Wrists (26%) and MTP (11%)
were most commonly involved, which was also observed if
only PD was taken into consideration. The distribution of
US synovitis over the different joint groups between pa-
tients who developed IA and those who did not develop IA
was comparable, except for the MTP, which were more in-
volved in the IA group.
Diagnostic value of US
The sensitivity and specificity of US synovitis in relation
to the incidence of IA if one joint was positive on US were
59% and 68%, respectively. Positive predictive value (PPV)
was 26%, and negative predictive value (NPV) was 74%.
When we required two joints to be US-positive to identify
an IA case, sensitivity decreased to 28% and specificity in-
creased to 86% (PPV 27%, NPV 73%). For the presence of
PD signal, sensitivity was 31% and specificity was 88% for
one positive PD joint (PPV 33%, NPV 67%). When two
joints were required, sensitivity decreased to 14% and spe-
cificity increased to 95% (PPV 38%, NPV 63%). If no joints
were positive on US, the NPV was 89%.
Association of independent variables with development
of IA
To quantify the associations between baseline characteris-
tics and incident IA at follow-up, we performed univariate
and multivariate logistic regression after multiple imput-
ation (M = 20). Results are presented in Table 3. Age (OR
1.06, 95% CI 1.03–1.09), morning stiffness > 30 minutes
(OR 2.39, 95% CI 1.20–4.73) and positive ACPA (OR 2.08,
95% CI 1.07–4.07) were associated with IA in univariate
analysis. Other clinical and demographic characteristics
did not differentiate patients with IA from non-IA pa-
tients. For the presence of US synovitis in at least one
joint, the OR was 3.03 (95% CI 1.69–5.41), and for the
presence of PD signal in at least one joint, the OR was
3.12 (95% CI 1.61–6.03). In the multivariate logistic re-
gression analysis, age (OR 1.06, 95% CI 1.03–1.10), morn-
ing stiffness > 30 minutes (OR 2.80, 95% CI 1.33–5.90),
positive ACPA (OR 2.35, 95% CI 1.13–4.87) and US syno-
vitis (OR 2.65, 95% CI 1.44–4.88) remained associated
with the development of arthritis during 1 year of follow-
up. If we replaced US synovitis with the presence of PD
signal (OR 3.44, 95% CI 1.71–6.95), the ORs for age and
Table 1 Baseline characteristics (n = 174)
Patients with IA (n = 31) Non-IA patients (n = 143) p Valuea
Female sex, n (%) 25 (81) 119 (83) 0.731
Age, years, mean (SD) 50 (8) 44 (12) 0.005
BMI, mean (SD) 26.8 (4.4) 27.5 (5.2) 0.534
SJC44, median (IQR) 0 (0–0) 0 (0–0) –
TJC44, median (IQR) 4 (2–9) 5 (3–8) 0.828
RF-positive, n (%) 9 (31) 37 (27) 0.628
ACPA-positive, n (%) 7 (24) 19 (14) 0.161
ESR, median (IQR) 10.5 (5–22) 10.5 (5–21) 0.824
Morning stiffness, minutes, median (IQR) 30 (30–60) 30 (15–60) 0.515
DAS28, mean (SD) 3.4 (1.1) 3.3 (1.0) 0.710
US synovitisb, n (%) 17 (59) 44 (32) 0.007
PD score > 0, n (%) 9 (31) 17 (12) 0.012
Abbreviations: ACPA Anti-citrullinated protein antibody, BMI Body mass index, DAS28 Disease Activity Score in 28 joints, ESR Erythrocyte sedimentation rate, IA In-
flammatory arthritis, PD Power Doppler, RF Rheumatoid factor, SJC44 Swollen joint count in 44 joints, TJC44 Tender joint count in 44 joints, US Ultrasound
a Depending on the distribution of the data, we used the independent t test or the Wilcoxon-Mann-Whitney test. Frequencies were compared using a chi-square
test (p ≤ 0.05)
b US synovitis defined as greyscale grade 2 or 3 and/or presence of PD (≥1)
Table 2 Distribution of ultrasound findings
US synovitisa, n (%) PD-positive, n (%)
IA (n = 31) Non-IA (n = 143) IA (n = 31) Non-IA (n = 143)
US-positive 17 (55) 45 (31) 9 (29) 17 (12)
MCP 3 (10) 9 (6) 1 (3) 3 (2)
PIP 3 (10) 1 (1) 2 (6) 0 (0)
Wrists 8 (26) 35 (24) 4 (13) 15 (10)
MTP 9 (29) 11 (8) 4 (13) 2 (1)
Abbreviations: IA Inflammatory arthritis, MCP Metacarpophalangeal joint, MTP
Metatarsophalangeal joint, PD Power Doppler, PIP Proximal interphalangeal
joint, US Ultrasound
aUS synovitis defined as greyscale grade 2 or 3 and/or presence of PD (≥ 1)
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morning stiffness were similar, but positive ACPA was not
associated with the development of arthritis.
Discussion
Sixteen percent of patients with early arthralgia devel-
oped IA after 1 year of follow-up, of whom 59% showed
US synovitis at baseline. Age, morning stiffness > 30 mi-
nutes and positive PD signal were all significantly associ-
ated with the development of IA after 1 year in a
multivariate model. Regarding the value of US in the
diagnostic workup of patients with early arthralgia at
risk for IA, US did not perform well in ruling in IA
(PPV 26%), but it did perform well in ruling out IA in
patients who did not have US synovitis (NPV 89%).
Up to now, researchers in few studies had investigated
subclinical synovitis in patients with arthralgia by making
use of imaging modalities. In an autoantibody-positive
arthralgia cohort, patients with positive US had an in-
creased risk for IA [14, 15]. This was confirmed in our
study, although only 15% of the patients were ACPA-
positive, and 24% was RF-positive. In another study in
which investigators evaluated patients with very early
hand symptoms, the presence of PD signal was associated
with IA in addition to clinical features (e.g., swollen joints)
and laboratory tests (e.g., serology, RF, ACPA) [20]. For
MRI, the results are not conclusive. Among a seropositive
arthralgia population, changes on MRI indicative of MCP
and PIP inflammation were not associated with the devel-
opment of arthritis at 3-year follow-up [21]. In contrast,
MRI findings in the most affected hand in patients with
clinically suspect arthralgia showed that subclinical MRI
inflammation preceded clinical arthritis by a few months.
This was also found in a subanalysis in a seronegative
arthralgia population [22, 23].
Our results should be interpreted in the light of the
choices we made. As explained in the Background sec-
tion above, we aimed for very early identification of IA.
For this study, we restricted the population to patients
with at least two painful joints as well as two criteria re-
lated to inflammation to be surer of the inflammatory
component. These inclusion criteria may have driven the
selection to a population at increased risk for polyarthri-
tis. We missed those patients who might be at risk for
IA but had only one painful (large) joint. However, our
inclusion criteria are in line with other arthralgia cohorts
and with the new EULAR guidelines regarding clinically
suspect arthralgia [22, 24]. Other forms of selection may
have occurred due to rheumatologists who recruited
clinically suspected patients with possibly more severe
symptoms [25]. In addition, 38 patients decided not to
participate without giving specific reasons, which could
have introduced a bias toward patients with more severe
complaints. These patients did not differ in age and sex
compared with the responders, but we do not know
whether their clinical symptoms differed. Information
bias could have occurred because some patients were
lost to follow-up (14%). This was anticipated at the start
of the study, so we included a telephone service if pa-
tients did not respond to their initial invitation for
follow-up. If those patients did not wish to return, they
Table 3 Association between baseline characteristics and development of inflammatory arthritis using univariate logistic regression
analysis and multivariate logistic regression analysis after multiple imputation (n = 174)
Univariate model Multivariate model including US synovitis Multivariate model including presence of PD
OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
Demographics
Age, years 1.06 (1.03–1.09) < 0.001 1.06 (1.03–1.10) < 0.001 1.07 (1.04–1.10) < 0.001
Sex 0.84 (0.42–1.70) 0.627
BMI 0.98 (0.92–1.04) 0.438
Clinical variables
Tender joints, range 0–44 1.01 (0.96–1.07) 0.676
DAS28 1.21 (0.92–1.58) 0.175
Morning stiffness > 30 minutes 2.39 (1.20–4.73) 0.013 2.80 (1.33–5.90) 0.007 3.34 (1.60–6.96) 0.001
Rheumatoid factor-positive 1.21 (0.65–2.23) 0.545
ACPA-positive 2.08 (1.07–4.07) 0.032 2.35 (1.13–4.87) 0.021
ESR 1.00 (0.98–1.02) 0.850
USa
US-positive 3.03 (1.69–5.41) < 0.001 2.65 (1.44–4.88) 0.007
PD-positive 3.12 (1.61–6.03) 0.001 3.44 (1.71–6.95) 0.001
Abbreviations: ACPA Anti-citrullinated protein antibody, BMI Body mass index, DAS28 Disease Activity Score in 28 joints, ESR Erythrocyte sedimentation rate, IA
Inflammatory arthritis (defined as clinical soft tissue swelling), PD Power Doppler, US Ultrasound
aUS synovitis definition: greyscale > 1 and/or PD > 0
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were asked a small set of questions to establish whether
they were at risk of IA. We saw no differences in their
baseline characteristics compared with those returning
to the clinic. We did not include these patients in the
analysis. Other bias could have been introduced by not
blinding the clinical examination and US examination,
because we included only patients with arthralgia. This
could have led unconsciously to less sensitive assessment
of clinical and US synovitis. However, at baseline, several
patients were excluded because of clinically apparent
arthritis confirmed by a trained research nurse. Another
item to take into account is that US is still considered
operator-dependent; therefore, the US examiners
scanned patients following the US study protocol as
training prior to the start of the study. In addition, US
examiners followed a protocol regarding acquisition and
scoring. Previous research regarding inter-reliability con-
firmed that a consensus scoring system combined with a
standardised acquisition protocol provided good inter-
reliability [26, 27]. In our definition of US synovitis, we
combined GS abnormalities with PD signal. Studies
showed that GS abnormalities also occur in non-
arthritic individuals, and especially the discriminative
value of GS score 1 is debatable [14, 28]. Therefore, we
used a threshold score of 2 for GS US abnormalities.
Conclusions
Sixteen percent of the patients with arthralgia developed
IA after 1 year of follow-up, of whom 59% showed US
synovitis at baseline. Positive PD signal, morning stiff-
ness and age were independently associated with the de-
velopment of IA after 1 year. Given the high NPV, US
has added value to identify which patients would not de-
velop into IA. Further research is recommended to con-
firm our results regarding the diagnostic value of US
synovitis to predict the progression to IA in patients
with early arthralgia.
Abbreviations
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Activity Score in 28 joints; DMARD: Disease-modifying anti-rheumatic drug;
ESR: Erythrocyte sedimentation rate; EULAR: European League Against
Rheumatism; GS: Greyscale; IA: Inflammatory arthritis; MCP: Metacarpophalangeal
joint; MTP: Metatarsophalangeal joint; MRI: Magnetic resonance imaging;
NPV: Negative predictive value; OMERACT: Outcome Measures in Rheumatology;
PD: Power Doppler; PIP: Proximal interphalangeal joint; PPV: Positive predictive
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